Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA4 | P22748 | 2/20 | 0.63 |
| ▸ | CA5A | P35218 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.63 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.55 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.55 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079137 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL10314115 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL15652629 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL7749645 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL14429226 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL18239900 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL19664275 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL2484480 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL15694578 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A | |
| SCHEMBL8004889 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | disclosed |
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | GIFU UNIVERSITY (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | UGCG, SGMS2, CERT1 | CA12 1528/4885CA1 2118/4885CA2 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.